DEDICATED TO THE CURE OF DENSE DEPOSIT DISEASE

 

For patients and families

For physicians

Research

Benefits

FAQ

 

Limited trial to study CDX-1135 in patients with DDD

Investigator-initiated study of CDX-1135 in C3G

"The opportunity to evaluate this drug in DDD patients is a major milestone for me and for all DDD patients. I hope it will lead to new possibilities and options for treating this dreadful disease. I thank everyone who has been there with us - who are as excited as I am to see where this takes us! Thank you to everyone who has helped make this day happen for me and for all of us with DDD!” – Jenna Smith

For patient information on this trial, click here. A more complete description of this FDA-approved study is available at ClinicalTrials.gov.

 

 

 

 

 

 

The 2013 DDD Family Conference was held Friday and Saturday, November 15-16.